Free Trial

HC Wainwright Lowers Earnings Estimates for Krystal Biotech

Krystal Biotech logo with Medical background

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities research analysts at HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for shares of Krystal Biotech in a research note issued to investors on Monday, June 30th. HC Wainwright analyst J. Pantginis now expects that the company will earn $1.26 per share for the quarter, down from their previous forecast of $1.71. HC Wainwright currently has a "Buy" rating and a $240.00 target price on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech's Q3 2025 earnings at $1.58 EPS, Q4 2025 earnings at $2.12 EPS and FY2025 earnings at $5.71 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%.

Several other analysts have also recently issued reports on the company. Chardan Capital reaffirmed a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday, May 7th. Citigroup decreased their price objective on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a report on Friday, May 16th. Finally, Guggenheim decreased their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $211.13.

Check Out Our Latest Analysis on KRYS

Krystal Biotech Stock Performance

Shares of KRYS traded up $1.66 during mid-day trading on Wednesday, hitting $143.01. 168,281 shares of the stock were exchanged, compared to its average volume of 287,292. The company has a market cap of $4.13 billion, a PE ratio of 34.38 and a beta of 0.67. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $219.34. The firm has a 50-day moving average of $138.07 and a two-hundred day moving average of $156.77.

Hedge Funds Weigh In On Krystal Biotech

Several large investors have recently modified their holdings of KRYS. Brooklyn Investment Group increased its position in shares of Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after purchasing an additional 105 shares during the last quarter. Twin Tree Management LP bought a new position in shares of Krystal Biotech during the 1st quarter valued at approximately $29,000. Fifth Third Bancorp increased its position in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after purchasing an additional 105 shares during the last quarter. Smartleaf Asset Management LLC grew its position in Krystal Biotech by 128.3% in the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company's stock valued at $58,000 after acquiring an additional 177 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in Krystal Biotech in the 1st quarter valued at $74,000. Institutional investors own 86.29% of the company's stock.

About Krystal Biotech

(Get Free Report)

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

Recommended Stories

Earnings History and Estimates for Krystal Biotech (NASDAQ:KRYS)

Should You Invest $1,000 in Krystal Biotech Right Now?

Before you consider Krystal Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.

While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines